RxDoctor Payments Data

Tayyaba Ali, MD

Child & Adolescent Psychiatry · Oklahoma City, OKNPI 1700292356

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 29 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 8 manufacturers, the largest accounting for just 21.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $130 and has fallen 60.1% since, to $52 in 2025.

$587in general payments, 2019–2025

Across 29 payments — averaging $20.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$127
  • Tris Pharma Inc$126
  • Vanda Pharmaceuticals Inc.$104
  • AbbVie$100
  • Otsuka America Pharmaceutical, Inc.$49
  • Supernus Pharmaceuticals, Inc.$38
  • plus $43 from 2 others

What the payments were for

  • Food & beverage$587100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$587 in reported general payments places this provider in the 60th percentile of 34 child & adolescent psychiatry providers in Oklahoma.

See all child & adolescent psychiatry providers in Oklahoma

Medicare billing

Part B allowed, 2024
$18,516
Medicare patients
49
Services billed
186

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole12$17,289
Aripiprazole23$4,795
Desvenlafaxine Succinate ErDesvenlafaxine Succinate12$1,365
Oxcarbazepine31$903
Duloxetine Hcl41$771
Bupropion XlBupropion Hcl12$463
Buspirone Hcl25$440
Olanzapine16$305
Trazodone Hcl54$293
Doxepin Hcl12$179
Lamotrigine28$158
Hydroxyzine Hcl25$154
Prazosin Hcl14$91
Sertraline Hcl17$66
Risperidone18$65

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$49$17,28912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 34 child & adolescent psychiatry providers in Oklahoma.

Other child & adolescent psychiatry in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →